Windlas Biotech (NSE:WINDLAS) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
87 GF Score
Price ₹844.25
GF Value ₹942.31
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Windlas Biotech Valuation Rank Related Terms

NSE:WINDLAS
87GF Score
Windlas Biotech Ltd NSE:WINDLAS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹844.25 is trading 10.4% below its estimated GF Value™ of ₹942.31. GuruFocus considers Windlas Biotech to be Modestly Undervalued.

Key valuation signals for NSE:WINDLAS:

  • Valuation Rank:
  • GF Value™: ₹942.31 vs. price of ₹844.25 (10.4% below fair value)
  • GF Score™: 87/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
87GF Score

Get the complete analysis for NSE:WINDLAS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹844.25
Price
₹942.31
GF Value